ClinicalTrials.gg
CompletedNCT02954601Updated Jul 12, 2018Results posted

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

A Phase 2 interventional study of ORMD-0801 (qd) and ORMD-0801 (bid) in Type 2 Diabetes Mellitus, sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,216th of 2,957
31 · median 90
Started
2016
with 102 others
Phase 2
391 of 3,304
24 open now
Registered
1,876th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,216th largest by enrollment of the 2,957 interventional ones that give a count, is one of 103 that started in 2016, is one of 391 in phase 2, and was the 1,876th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive.

Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme.

Read the detailed description

Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On Day 4, each subject was randomized to a treatment sequence that included three treatment assignments for each of three treatment Periods according to the randomization scheme.

Pre-assignment Details The number of participants receiving each Intervention, in each Period, is reported.

Subjects received the randomized treatment from Day 4 through Day 8. There was a 24-hour single-blind placebo washout on Day 9. Each subject received placebo for one of the three treatment periods. Each subject also received 1 of the 3 active doses randomly in each of the two other treatment periods respectively. The dosing order is random.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Oral Insulin
  • DM T2 (Diabetes Mellitus Type 2)
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, age 20 to 75 years, inclusive with type 2 diabetes mellitus.
  • At Visit 2/Period 1/Day 1, subjects will have been treated for their diabetes by metformin (≥1000 mg/day; any type and regimen), metformin and a DPP-4 inhibitor ( Dipeptidyl-Peptidase)-4), metformin and an SGLT-2 (Sodium-glucose co-transporter 2) inhibitor, metformin and TZD (Thiazolidinediones), or metformin and sulfonylurea. Subjects will have been on a stable regimen of metformin (defined as the same metformin dose and type) and other treatments for at least 8 weeks prior to Visit 2/Period 1/Day 1.
  • (BMI) between 25 and 40 kg/m2, inclusive, at Screening.
  • (HbA1c) between ≥7.5 and ≤10.5% at Screening.
  • Fasting serum glucose greater than or equal to 126 mg/dL at Screening.
  • Females of must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test at Visit 2/Day 1 for all study Periods.
  • Females who are not of childbearing potential are defined as:

    i. (defined as at least 12 months with no menses in women ≥45 years of age) ii. Has had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR iii. Has a congenital or acquired condition that prevents childbearing.

  • Females of childbearing potential agree to avoid becoming pregnant while receiving study treatment and for 14 days after the last dose of study treatment by complying with one of the following:

    i. practice abstinence† from heterosexual activity OR ii. Use (or have her partner use) acceptable during heterosexual activity.

Exclusion criteria

Exclusion Criteria:

  • Usage of anti-diabetic agents other than metformin, sulfonylurea, SGLT-2 inhibitors, TZD, or DPP-4 inhibitors within 6 weeks prior to Visit 2/Period 1/Day 1.
  • Presence of any endocrine disease according to the Investigator (euthyroid subjects on replacement therapy will be included if the dosage of thyroxine is stable for at least six weeks prior to Screening).
  • Clinical diagnosis of type 1 diabetes.
  • Fasting serum glucose >300 mg/dL at Screening; a single repeat test is allowable.
  • Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤50 mg/dL in the absence of symptoms of hypoglycemia at Screening.
  • Presence of any clinically significant condition (in the opinion of the Investigator) that might interfere with the evaluation of study medication, such as significant renal, hepatic, gastrointestinal (GI), cardiovascular (CV), immune disease, blood dyscrasias or any disorders causing hemolysis or unstable red blood cells, or clinically important hematological disorders (i.e. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) at Screening.
  • Presence or history of cancer within the past 5 years of Screening, with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.

    1. A subject with a history of >5 years prior to Screening should have no evidence of residual or recurrent disease.
    2. A subject with a history of melanoma, leukemia, lymphoma, or renal carcinoma is excluded.
  • Laboratory abnormalities at Screening including:

    1. C-peptide \< 1.0 ng/mL;
    2. Positive pregnancy test in females of (at Screening and Visit 2/Periods 1-3/Day 1);
    3. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X (1.5 times) the
    4. Elevated liver enzymes ( (ALT), alanine aminotransferase (AST), alkaline phosphatase) >2X the upper limit of normal.
    5. Very high triglyceride levels (>600 mg/dL); a single repeat test is allowable.
    6. Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.
  • Positive history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic or C, primary biliary cirrhosis, or active symptomatic gallbladder disease.
  • Positive history of .
  • Use of the following medications:

    1. History of use of insulin for more than 1 week within 6 months prior to and none within 6 weeks prior to Visit 2/Period 1/Day 1.
    2. History of use of aprotinin at any time prior to Screening (e.g., Trasylol, any type or dose).
    3. Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.
    4. Administration of systemic long-acting within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 30 days prior to Screening. Intra-articular and/or topical corticosteroids are not considered systemic.
    5. Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as discussed above), and or immunomodulating agents.
  • Subject is on a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide), within 8 weeks prior to Screening. Subjects who have had bariatric surgery are also excluded.
  • Subject is pregnant or breast-feeding.
  • Subject has a Screening systolic blood pressure ≥165 mmHg or diastolic blood pressure ≥100 mmHg. Subjects will be allowed to take a BP rescue medication.
  • Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking) at Screening.
  • Any clinically significant abnormality at Screening or cardiovascular disease. Clinically significant cardiovascular disease will include:

    1. History of stroke, , or myocardial infarction within 6 months prior to Screening,
    2. History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or
  • One or more to metformin.
  • At the Principal Investigator's discretion, any condition or other factor that is deemed unsuitable for subject enrollment into the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Active comparator
    Placebo

    Placebo (fish oil)

    Other: Placebo

  • Active comparator
    Dose1

    Dose 1 ORMD-0801 (qd)

    Drug: ORMD-0801 (qd)

  • Active comparator
    Dose2

    Dose 2 ORMD-0801 (bid)

    Drug: ORMD-0801 (bid)

  • Active comparator
    Dose 3

    Dose 3 ORMD-0801 (tid)

    Drug: ORMD-0801 (tid)

Interventions

  • Dose 1 = ORMD-0801 (qd)

    Also known as: Oral Insulin

  • Dose 2 = ORMD-0801 (bid)

    Also known as: Oral Insulin

  • Dose 3 = ORMD-0801 (tid)

    Also known as: Oral Insulin

  • OtherPlacebo

    fish oil placebo

    Also known as: fish oil

06

What researchers measure

Primary outcomes

  1. Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)

    Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)

    Time frame: Day 3 (run-in) and Day 8 (Day 5 of Active treatment)

Secondary outcomes

  1. Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.

    For each dose, calculate the ratio of the C-Peptide measurement area-under-the-curve (ng-hr/mL) Day 8 to the C-peptide measurement area-under-the-curve (ng-hr/mL) Day 3. This ratio is called the C-peptide Ratio.

    Time frame: Day 3 and Day 8

  2. The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo

    The number of safety parameter hypoglycemic events for single and multiple doses of ORMD-0801 vs placebo.

    Time frame: Day 3 through Day 8 of treatment

  3. Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose

    Calculate the difference between pre-treatment (Day 3) and end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo.

    Time frame: Day 3 and Day 8 (two timepoints)

07

Results

Posted Jul 12, 2018

Participant flow

Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On Day 4, each subject was randomized to a treatment sequence for each of three treatment periods, each period was either placebo or 1 of the 3 treatments). All subjects received placebo and only 2 of the 3 treatments.

First Intervention (Five Days)
Participant flow — First Intervention (Five Days)
MilestonePlaceboDose1Dose2Dose 3
Started11687
Completed11677
Not completed0010
Withdrew: Withdrawal by subject0010
Second Intervention (Five Days)
Participant flow — Second Intervention (Five Days)
MilestonePlaceboDose1Dose2Dose 3
Started11686
Completed11686
Not completed0000
Third Intervention (Five Days)
Participant flow — Third Intervention (Five Days)
MilestonePlaceboDose1Dose2Dose 3
Started9868
Completed9868
Not completed0000

Outcome measures

PrimaryChange in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)

Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)

Time frame:
Day 3 (run-in) and Day 8 (Day 5 of Active treatment)
Reported as:
Mean · mg/dL
Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)
mg/dLPlaceboDose 1Dose 2Dose 3
Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)-4.94 ± 4.418-10.00 ± 7.236-1.21 ± 7.397-11.42 ± 8.451
Statistical analysis
  • Placebo vs Dose 1 vs Dose 2 vs Dose 3 · Mixed Models Analysis · p = 0.1311
SecondaryCalculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.

For each dose, calculate the ratio of the C-Peptide measurement area-under-the-curve (ng-hr/mL) Day 8 to the C-peptide measurement area-under-the-curve (ng-hr/mL) Day 3. This ratio is called the C-peptide Ratio.

Time frame:
Day 3 and Day 8
Reported as:
Mean · ratio
Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.
ratioPlaceboDose 1Dose 2Dose 3
Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.0.97 ± 0.0341.01 ± 0.0561.03 ± 0.0470.93 ± 0.051
SecondaryThe Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo

The number of safety parameter hypoglycemic events for single and multiple doses of ORMD-0801 vs placebo.

Time frame:
Day 3 through Day 8 of treatment
Reported as:
Number · number of hypoglycemic events
The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo
number of hypoglycemic eventsPlaceboDose 1Dose 2Dose 3
The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo3245
SecondaryCalculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose

Calculate the difference between pre-treatment (Day 3) and end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo.

Time frame:
Day 3 and Day 8 (two timepoints)
Reported as:
Mean · mg/dL
Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose
mg/dLPlaceboDose 1Dose 2Dose 3
Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose-4.11 ± 5.080-13.96 ± 7.7751.13 ± 7.772-16.78 ± 8.613
Statistical analysis
  • Placebo vs Dose 1 vs Dose 2 vs Dose 3 · Mixed Models Analysis · p = 0.3061

Adverse events

Collected over One Year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/31 (0%)0/31 (0%)12/31 (38.7%)
Dose 10/20 (0%)0/20 (0%)7/20 (35%)
Dose 20/21 (0%)0/21 (0%)11/21 (52.4%)
Dose 30/21 (0%)0/20 (0%)3/20 (15%)
Most frequent other events
Most frequent other events
EventPlaceboDose 1Dose 2Dose 3
Metabolism and Nutrional DisordersMetabolism and nutrition disorders7/315/206/212/20
HypoglycemiaMetabolism and nutrition disorders2/311/204/211/20
Gastrointestinal disordersGastrointestinal disorders3/311/202/210/20
Nervous System DisordersNervous system disorders1/310/202/210/20
Eye DisordersEye disorders0/310/200/211/20
Muskuloskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders1/311/200/210/20
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders0/310/201/210/20

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
Mean57.27 ± 7.0057.17 ± 11.3759.5 ± 7.0358.71 ± 7.5457.72 ± 7.77
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
Female351312
Male816419
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
Hispanic or Latino434617
Not Hispanic or Latino733114
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
American Indian or Alaska Native00000
Asian00112
Native Hawaiian or Other Pacific Islander00000
Black or African American21104
White955625
More than one race00000
Unknown or Not Reported00000
Child-Bearing Status
Child-Bearing Status(Participants)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
Not Applicable (Male)816419
Of Childbearing Potential00000
Post Hysterectomy11024
Surgically Sterilized02002
At least 1 year Post-Menopausal22116
Alcohol History
Alcohol History(Participants)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
Never632516
Current534214
Former00101
Tobacco History
Tobacco History(Participants)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
Never855523
Current10012
Former21216
Caffiene History
Caffiene History(Participants)PlaceboORMD-0801 qdORMD-0801 BidORMD-0801 TidTotal
Never11114
Current1056526
Former00011
08

Study locations

1 site
  • Orange County Research Center
    Tustin, California 92780, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of Feb 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2016
First posted
Nov 3, 2016
Start
Oct 2016
Primary completionActual
Feb 24, 2017
CompletionActual
Mar 15, 2017
Results first posted
Jul 12, 2018
Last update
Jul 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02954601
Lead sponsor
Oramed, Ltd.
Collaborators
Integrium
Responsible party
Sponsor
First posted
Nov 3, 2016
Start date
Oct 2016
Primary completion
Feb 24, 2017
Completion
Mar 15, 2017
Results posted
Jul 12, 2018
Last update
Jul 12, 2018

Study contacts

Joel M Neutel, M. D.
principal investigator · Orange County Research Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ORMD-0801

Start the discussion